Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9593015 | PMC |
| http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2022.08.018 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Complement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trial.
Nat Commun
January 2025
Grid Therapeutics, Durham, NC, USA.
GT103 is a first-in-class, fully human, IgG3 monoclonal antibody targeting complement factor H that kills tumor cells and promotes anti-cancer immunity in preclinical models. We conducted a first-in-human phase 1b study dose escalation trial of GT103 in refractory non-small cell lung cancer to assess the safety of GT103 (NCT04314089). Dose escalation was performed using a "3 + 3" schema with primary objectives of determining safety, tolerability, PK profile and maximum tolerated dose (MTD) of GT103.
View Article and Find Full Text PDFInfluence of government policies on handwashing and vaccine uptake in Kenya, Uganda, and Tanzania to prevent and control COVID-19: a systematic review.
Front Public Health
January 2025
Amref Health Africa, Kampala, Uganda.
Introduction: The government's role in influencing policies related to Coronavirus disease 2019 (COVID-19) vaccine distribution and handwashing practices is essential in controlling the spread of severe acute respiratory syndrome coronavirus 2.
Methods: This study aimed to systematically review published studies to explore the influence of government policies on handwashing and vaccine uptake in Kenya, Uganda and Tanzania to prevent and control COVID-19. A comprehensive search strategy was applied across three databases, and eligibility was determined using strict inclusion and exclusion criteria.
An inflammatory state defines a high-risk T-lineage acute lymphoblastic leukemia subgroup.
Sci Transl Med
January 2025
Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C4, Canada.
Article Synopsis
- T-lineage acute lymphoblastic leukemia (ALL) presents as an aggressive cancer with diverse subtypes, making traditional classification difficult.
- A multiomics analysis of bone marrow samples revealed a specific subset of T-lineage ALL with active inflammatory and stem gene programs, showing unique biological and treatment response characteristics.
- A computational inflammatory gene signature scoring system was developed to better classify patients, identifying a high-risk subtype that could guide targeted therapies for more effective treatment approaches.
Impact of DNA Ligase 1 Genotypes on Childhood Acute Lymphocytic Leukemia.
In Vivo
December 2024
Terry Fox Cancer Research Laboratory, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan, R.O.C.;
Background/aim: Genetic polymorphisms in DNA repair mechanisms can modulate overall DNA repair capacity, potentially influencing individual susceptibility to cancer. This study investigated the relationship between polymorphic variations in DNA ligase 1 and the risk of childhood acute lymphocytic leukemia (cALL).
Materials And Methods: The genotypes of DNA ligase 1 rs20579 were determined using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis.
Effectiveness of different gums on modulating of glycemic indices in adults: a systematic review and meta-analysis.
J Diabetes Metab Disord
June 2025
Student Research Committee, Department of Food Science and Technology, Faculty of Nutrition and Food Science, Tabriz University of Medical Sciences, Tabriz, Iran.
Background: Functional foods have been widely used as the anti-diabetic agents worldwide. Existing studies presented conflicting results of anti-hyperglycemic properties of gums. This systematic review and meta-analysis study evaluated the existing trials and determined the efficacy of different gums on glycemic indices.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!